// App-Quantinova.ai

e14012 : Anti-PD-1 to enhance NK-cell cytotoxicity towards CD30+ Hodgkin lymphoma induced by CD30/CD16A TandAb AFM13.

Researchers

Presenter

  • Martin Treder

Principal Investigators

  • Xing Zhao

  • Narendiran Rajasekaran

  • Uwe Reusch

  • Jens-Peter Marschner

  • Holbrook Edwin Kohrt

Medical Centers

  • Affimed, Heidelberg, Germany

  • Tissue Engineering and Stem Cells Research Center, Department of Immunology, Guiyang Medical University, Guiyang, China

  • Center for Clinical Sciences Research Stanford, Stanford, CA

Locations

  • United States

  • Germany

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • Peripheral blood mononuclear cell

  • Cluster of Differentiation 30

  • Fc gamma RIIIa

Drug/Treatment

  • AFM 13

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved